Cingulate (CINGW) Common Equity (2021 - 2026)
Cingulate's (CINGW) quarterly Common Equity came in at $23.5 million in Q2 2026, down 90.22% on a YoY basis from $240.0 million in Q2 2025, and up 835.35% quarter-over-quarter from $2.5 million in Q4 2025.
Analysis
Cingulate (CINGW) Common Equity (2021 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Common Equity for 6 consecutive years, with $23.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Common Equity fell 90.22% year-over-year to $23.5 million; the trailing twelve-month figure through Jun 2026 stood at $23.5 million (down 90.22% YoY), and the FY2025 full-year result was $2.5 million, down 98.95% from the prior year.
- Common Equity rose to $23.5 million in Q2 2026 per CINGW's latest filing, from $2.5 million in the prior quarter.
- Across five years, Common Equity topped out at $240.0 million in Q2 2025 and bottomed at -$6.9 million in Q4 2023.
- Historically, Common Equity has averaged $19.3 million across 5 years, with a median of $3.9 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Common Equity tumbled 276.95% in 2023, then surged 12595.65% in 2024.
- Over 5 years, Common Equity stood at $3.9 million in 2022, then sank by 276.95% to -$6.9 million in 2023, then soared by 208.53% to $7.5 million in 2024, then sank by 66.35% to $2.5 million in 2025, then surged by 835.35% to $23.5 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $23.5 million, $2.5 million, and $3.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.46 Bn | 623.70 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 440.11 Bn | 433.54 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 365.04 Bn | 357.90 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 85.49 Bn |
| 6 | Sanofi | 52.47 Bn | 45.09 Bn | 10.79 Bn | 80.86 Bn |
| 7 | Revolution Medicines | 44.26 Bn | 44.26 Bn | - | 2.61 Bn |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 6.34 Bn |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | 6.40 Bn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | 23.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23.47 Mn |
| Dec 31, 2025 | 2.51 Mn |
| Sep 30, 2025 | 3.47 Mn |
| Jun 30, 2025 | 240.00 Mn |
| Mar 31, 2025 | 5.93 Mn |
| Dec 31, 2024 | 7.46 Mn |
| Sep 30, 2024 | 12.04 Mn |
| Jun 30, 2024 | 3.08 Mn |
| Mar 31, 2024 | 3.22 Mn |
| Dec 31, 2023 | -6.87 Mn |
| Sep 30, 2023 | -96,334.00 |
| Jun 30, 2023 | -6.10 Mn |
| Mar 31, 2023 | 81,614.00 |
| Dec 31, 2022 | 3.88 Mn |
| Sep 30, 2022 | 8.37 Mn |
| Jun 30, 2022 | 12.18 Mn |
| Mar 31, 2022 | 16.02 Mn |
| Dec 31, 2021 | 20.84 Mn |
| Sep 30, 2021 | 3.08 Mn |
| Jun 30, 2021 | 1.90 Mn |